Product innovations selenium in intensive care medicine
Keyhole Limpet Hemocyanin (KLH) Integrated concept
Interferon therapy D-Galactose

D-Galactose for inhibiton of liver metastases

   
D-Galactose or D-Galactose rich polysaccharides exhibits anti-metastatic effects. Liver bound galactose specific lectins are important binding sites for metastasizing tumor cells expressing free galactose residues. The carbohydrate D-Galactose binds to the liver lectins thus blocking the sites and inhibiting liver metastases. Galasyn® is in the phase III clinical trials. The first marketing authorization in Europe is expected in the year 2003/2004.

Patent information:
„Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumoren“
  • European-Patent-No. 0249008
    Granted: 15.09.1993
„Agent and Method for the Prevention of Metastases of Malignant Tumors“ => „Mittel und Verfahren zur Verhinderung von Metastasen maligner Tumore“
  • USA-Patent-No: 4,946,830
    Granted: 07.08.1990
„Use of monosaccharides and/or glycoconjugates containing these monosaccharides“
  • Japan-Patent-No: 2901614
    Granted: 19.03.1999